Navigation Links
Accelreon Pharma's ACE-031Shown to Increase Muscle Mass in,Preclinical Studies

LUCCA, ITALY, ­ May 14, 2007-Acceleron Pharma, Inc., a biopharmaceutical company developing therapeutics for the treatment of musculoskeletal, metabolic and cancer-related diseases, today announced results of a preclinical study with ACE-031 that demonstrated the ability of the compound to increase muscle mass and strength in normal mice and in murine models of muscular dystrophy. ACE-031 inhibits negative regulators of muscle to increase muscle mass and strength as a potential treatment for neuromuscular diseases and cancer-related muscle loss. The data was presented on Sunday, May 13 at the Gordon Research Conference on Myogenesis in Lucca, Italy. ³

Acceleron is encouraged by the significant outcomes and positive data generated by ACE-031 spanning numerous preclinical models of muscle loss², said Jas Seehra, Ph.D., Chief Scientific Officer of Acceleron. ³ACE-031 and related Acceleron compounds consistently demonstrate substantial increases in skeletal muscle mass and strength.² ACE-031, a protein therapeutic based on the activin receptor type IIB (ActRIIB), is the first of several compounds Acceleron is developing for the treatment of diseases involving the loss of muscle mass, strength and function. ActRIIB binds to myostatin (GDF-8) and other negative regulators of muscle mass and strength. Over-expression of myostatin has been shown to cause a loss in muscle mass and strength, and inhibition of myostatin results in the selective increase in skeletal muscle mass and strength. In preclinical models, ACE-031 increased skeletal muscle mass and strength in disease models of amyotrophic lateral sclerosis (ALS), muscular dystrophy, glucocorticoid-induced muscle loss and age-related muscle loss (sarcopenia).

ACE-031 offers the potential for an entirely new type of therapy for the treatment of various muscle wasting conditions. ³The clinical potential of ACE-031 to selectively increase skeletal muscle will offer
'"/>




Page: 1 2 3

Related medicine technology :

1. Acceleron Pharmas ACE-031 Increases Muscle Mass and Strength in Preclinical Studies
2. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
3. Rapid HIV Testing Increases Possibility of Treatment
4. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
5. ProtoKinetixs AAGP Dramatically Increases Recovery Rate of Cryopreserved Stem Cells
6. Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant
7. Auxilium Announces New Data That Show Total Testosterone Blood Levels Increase Significantly Following Switch from AndroGel(R) to Testim(R)
8. New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory Properties and Increased Health Benefits
9. MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen
10. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
11. Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)

Post Your Comments:
(Date:11/25/2009)...DELFT,TheNetherlandsandJOHANNESBURG,November25/PRN...ndPyxisDiscoveryannouncedtoday,thattheyhavesigneda...s,services. , Pyxis,sworldclasscomputationalc...hiThemba,sservicedivisiontoprovidemedicinaland,syn...yxis,internationalclientnetwork.iThembaPharmaceut...
(Date:11/25/2009)...MOUNTAINVIEW,Calif.,Nov.25/PRNewswire/-- ChemoCen...afromtheCompany,sPROTECT-1(theProspectiveRandomize...icet-EN(TM)(CCX282-B)inpatientswithmoderate-to-sev...favorablesafetyandtolerabilityprofile.Thestudydemo...diseaseseverityasdefinedasa70-pointdecreaseintheCr...
(Date:11/24/2009)...PITTSBURGH,Nov.24/PRNewswire/-- ,, WHAT:RomHoub...llowinganautoaccident,wasactuallyfullyconsciousand...mericasegment.TheDynaVoxEyeMaxwasfeaturedinthesegm...herconditionscanunlockcommunication. ,, WHEN:Go...ineat www.dynavoxtech.com ,, WHO:RomHoub...
Breaking Medicine Technology:iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Watson Files FDA Application for Generic Mucinex 28R 29 D 48412 1Watson Files FDA Application for Generic Mucinex 28R 29 D 48412 2Watson Files FDA Application for Generic Mucinex 28R 29 D 48412 3Swim Yourself Slim This Summer With AXA PPP Healthcares Nutrition and Fitness Expert Guide 48410 1Swim Yourself Slim This Summer With AXA PPP Healthcares Nutrition and Fitness Expert Guide 48410 2Swim Yourself Slim This Summer With AXA PPP Healthcares Nutrition and Fitness Expert Guide 48410 3Forterus Inc Announces Special Board Meeting 3B Nominates Jeff Walton Former Bear Stearns President to Board of Directors 48408 1Forterus Inc Announces Special Board Meeting 3B Nominates Jeff Walton Former Bear Stearns President to Board of Directors 48408 2
...N, 12 July 2007 - Cancer drug developer Antisoma p...ata from its phase,II trial of ASA404 in recurrent...mpares patients receiving ASA404 plus chemotherapy... (n=38). The main,findings are as follows: , * The...ession in,the ASA404 arm compared with the control...
...LE, July 11, 2007 /PRNewswire-FirstCall/ -- On Wed....m. Eastern/10:30 p.m.,Central European Time membe...eam will host a conference call to discuss today,s...II/III RAPID trial,comparing CHOP-R to CPOP-R, in ... standard CHOP-R, in first-line treatment of patie...
Other Medicine Technology:Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial 2Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial 3Cell Therapeutics, Inc. Management to Discuss Today's Announcement,of Interim Pixantrone Study Results 2
(Date:11/25/2009)...iscovery that grew out of a collaboration between ...fer hope to the nearly 10 million Americans who su...o known as hardening of the arteries, peripheral a...roblem in which narrowed arteries reduce blood flo...flag for vascular disease, heart attack and stroke...
(Date:11/25/2009)... Evaluation and treatment clinics to resume...ock (Vocus) November 25, 2009 -- Centegra Health S...nd H1N1 vaccine shots at four Centegra Primary Car... of vaccine has arrived. The clinics are at CPC si...y and will be open as follows: ,   Fro...
(Date:11/25/2009)...v.25/PRNewswire/-- MISSIONSkincare ®isproudto...ude.AspartofGNC,sannualSt.Jude ThanksandGiving cam...e,s new SUPER-C(TM)LipBalm willbedonatedtoSt.Jud...ea$1,$5or$10donationatcheckoutatoneoftheir5,000+re...millionforSt.Judeduringtheir2009 ThanksandGiving c...
(Date:11/25/2009)...reat colorectal cancer also can reverse a rare sto...therapy for the disease, researchers at Vanderbilt...trier,s disease causes thickening of the stomach l... as well as anemia and swelling in the feet and an...d risk for gastric cancer. Previously, the only ef...
(Date:11/25/2009)... Nationwide Imaging Services, known as one ... diagnostic imaging equipment, now offering a tota...ancing options, service and installation with acqu... Technologies of California) , ...nwide Imaging Services is proud to announce its ac...
Breaking Medicine News(10 mins):Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2Health News:Vanderbilt scientists report first effective medical therapy for rare stomach disorder 2Health News:Nationwide Imaging Services, Inc., Leader In Diagnostic Imaging Equipment, Announces Acquisition Of Kosmic Medical, Inc. (dba Atlas Medical Technologies of California) 2Health News:Nationwide Imaging Services, Inc., Leader In Diagnostic Imaging Equipment, Announces Acquisition Of Kosmic Medical, Inc. (dba Atlas Medical Technologies of California) 3
...24 United American Healthcare,Corporation (Nasdaq...ncial,results for the second fiscal quarter ended ...ket close. The Company will host a conference call...onal investors and analysts. Individual investors ...
...n. 24 The Advisory Board,Company (Nasdaq: ABCO )...ference call hosted by Frank J. Williams, Chairman...baum, Chief Financial Officer, to discuss the,Comp...mpany plans to release its third quarter financial...
...ccreditation standards for Specialty Pharmacy, Wor...INGTON, Jan. 24 URAC called for public,comment to...The programs,are Specialty Pharmacy, Mail Service ...ng Pharmacy Benefit,Management Accreditation stand...
.... 24 MediKeeper,( http://www.medikeeper.com ), a ...ealth and wellness industry, today announced its a...s Senior VP/Sales to lead expansion of,strategic s...lth and,wellness. Its Personal Health Record (PHR)...
...ill Benefit HIV/AIDS Patients in Broward County an...on-Cutting Ceremony, Refreshments, Free HIV Testi...e Foundation (AHF) will mark the opening of its ne... 10:00 a.m. This,festive community open house will...
...have discovered that mice genetically engineered t...ound deafness and seizures. The finding suggests a...auses of deafness and epilepsy in humans. , More ... the team, led by scientists at the University of ...
Other Medicine News:Health News:The Advisory Board Company Schedules Third Quarter Investor Conference Call for February 5, 2008 2Health News:URAC Seeks Public Comment on Standards for New Pharmacy Accreditation Programs 2Health News:URAC Seeks Public Comment on Standards for New Pharmacy Accreditation Programs 3Health News:URAC Seeks Public Comment on Standards for New Pharmacy Accreditation Programs 4Health News:Global Sales Veteran Jack McGovern Joins MediKeeper 2Health News:AIDS Healthcare Foundation Hosts Grand Opening of Wilton Manors 'Out of the Closet' & 'AHF Pharmacy' 2Health News:AIDS Healthcare Foundation Hosts Grand Opening of Wilton Manors 'Out of the Closet' & 'AHF Pharmacy' 3Health News:Deafness and seizures result when mysterious protein deleted in mice 2Health News:Deafness and seizures result when mysterious protein deleted in mice 3
HemoCue 201 DM System, Glucose
Triage® C. difficile Panel
Bartels® C. Difficile Toxin A Antigen EIA with Controls
... Toxin A C. difficile Rapid Toxin A Test gives you...minutes. When it might be C. difficile, you can't ...nly a few tests a day or sends out its suspected C...C. difficile Rapid Toxin A Test will cut costs and...
Medicine Products: